Gallbladder emptying and gallstone formation: A prospective study on gallstone recurrence

doi:10.1053/gast.1996.v111.pm8780583

Gastroenterology

Volume 111, Issue 3, September 1996, Pages 765-771

https://doi.org/10.1053/gast.1996.v111.pm8780583 Get rights and content

Abstract

BACKGROUND & AIMS: Gallbladder emptying is reduced in many patients with cholesterol gallstones. To clarify the role of impaired gallbladder motility in recurrent gallstone disease, the effect of gallbladder emptying on the formation of recurrent stones was studied prospectively. METHODS: In 54 consecutive patients with single radiolucent gallbladder stones, postprandial gallbladder emptying was assessed sonographically before lithotripsy and 1.8 +/- 0.1 years (mean +/- SE) after gallstone disappearance. Patients were followed up for gallstone recurrence for 0.6-4.1 years (median, 2.6 years). RESULTS: After gallstone disappearance, gallbladder fasting volume (33.7 +/- 3.4 vs. 27.8 +/- 3.0 mL; P = 0.007) and residual volume (12.6 +/- 1.9 vs. 9.7 +/- 1.3 mL; P = 0.010) decreased, whereas the ejection fraction remained unchanged. However, gallbladder volume did not differ whether initial or recurrent stones were present. Gallbladder emptying was more impaired in patients with than patients without later recurrence (47% +/- 5% vs. 63% +/- 2%; P = 0.001). Cox analysis showed that gallbladder emptying was an independent determinant of the risk of gallstone recurrence (P = 0.002). Within 3 years, recurrent stones formed in 53% (actuarial analysis) of patients with an ejection fraction of < 60% but in only 13% of patients with an ejection fraction of > or = 60%. CONCLUSIONS: Gallbladder emptying is an important factor in the formation of recurrent gallstones. (Gastroenterology 1996 Sep;111(3):765-71)

References (0)

Cited by (88)

Discovery and exploration of novel somatostatin receptor subtype 5 (SSTR5) antagonists for the treatment of cholesterol gallstones
2024, European Journal of Medicinal Chemistry
The shortage of cholesterol gallstones treatment intensifies the need to discover of effective small molecule drugs. Clinical follow-up and studies have found that activation of somatostatin receptor subtype 5 (SSTR5) reduce gallbladder contraction and thus increase the risk of cholesterol gallstones, implying that antagonizing SSTR5 may promote gallbladder emptying and reduce the formation of gallstones. Herein, we discovered novel SSTR5 antagonists and firstly investigated its effects on cholesterol gallstone. From loperamide, a reported seed structure with micromole activity, we identified optimal compound 23 as an SSTR5 antagonist exhibiting single-digit nanomolar potency, low hERG inhibition and oral availability. Further in vivo evaluation revealed that 23 significantly promoted gallbladder emptying. Moreover, in a mouse cholesterol gallstone model, 23 (3 mg/kg) effectively reduced the cholesterol gallstones formation, showing better efficacy than the clinical first-line drug UDCA (60 mg/kg), providing a new insight into the development of anti-gallstone drugs.
An Update on Biliary Dyskinesia
2019, Surgical Clinics of North America
Citation Excerpt :
The clinical relevance of this finding is unclear. Generally, a gallbladder ejection fraction of greater than 60% indicates normal gallbladder function and can support nonoperative management in patients with cholelithiasis.42,43 Regardless, primary care providers and some gastroenterologists have interpreted a high gallbladder ejection fraction as abnormal.
EASL Recognition Award Recipient 2017: Prof. Gustav Paumgartner
2017, Journal of Hepatology
Targets for current pharmacologic therapy in cholesterol gallstone disease
2010, Gastroenterology Clinics of North America
Pathogenesis of gallstones
2010, Gastroenterology Clinics of North America
Citation Excerpt :
Patients with good postprandial contraction often have increased fasting and residual gallbladder volumes compared with normal controls.32 Prospective studies also indicate that impaired postprandial gallbladder motility is an independent risk factor for gallstone recurrence after successful treatment with extracorporeal shockwave lithotripsy.33 It is less well appreciated that significant periodic gallbladder emptying also occurs during the fasting state (20%–30% emptying in the fasting state vs 70%–80% emptying after a meal) at 1- to 2-hour intervals, associated with the cycle of the intestinal migrating motor complex and with a rise of plasma motilin levels.34
Mandatory and optional function tests for biliary disorders
2009, Best Practice and Research: Clinical Gastroenterology
Citation Excerpt :
Gallbladder function was determined before and after dissolution therapy. The risk for gallstone recurrence was approximately four-fold higher in patients with a gallbladder ejection fraction of <60% (53 vs. 13% three years after dissolution therapy) [35]. Another trial including 54 patients who also underwent ESWL plus UDCA for the dissolution of gallstones showed that stone recurrence was postponed in patients with postprandial residual gallbladder volume <6 ml (recurrence rate 21 vs. 53% two years after treatment) [36].
Function tests in gastroenterology and hepatology aim to provide criteria for diagnosis of specific disorders and for prediction of patient responses to therapy. This review focuses on the utility of function tests in the management of gallstone disease and functional biliary disorders. In gallstone disease, function tests may be considered in the selection of candidates for nonsurgical therapy of gallbladder stones only. In cases of suspected functional biliary disorders, experts have advocated the use of classical noninvasive tests such as hepatobiliary scintigraphy. However, unequivocal evidence for their utility in diagnosis or patient selection for invasive treatment is yet to be provided. Recently, more advanced noninvasive tests such as real-time ultrasonography or secretin-stimulated magnetic resonance cholangiopancreaticography have been described. Controlled trials using these novel techniques may provide a rationale for the use of function tests in clinical management of calculous and acalculous biliary diseases, but are currently not available.

View all citing articles on Scopus

View full text